BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.4%

Neg 0% Neu 86.4% Pos 0%

BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.